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Introduction: Almost all small-cell lung cancers (SCLC) and car-
cinoid tumors express neuroendocrine differentiation (NED), and 
10% to 20% of non–small-cell lung cancers (NSCLC) are associ-
ated with NED. Although distinct clinical features and histology 
of SCLC and carcinoid tumors are well recognized, the clinical 
significance and the molecular basis of NED in NSCLC remain 
unclear.
Methods: To explore the potential molecular pathway involved in 
NED of NSCLC and its clinical relevance, we conducted investiga-
tions using an NSCLC cell line (NCI-H157) as a NED induction 
model, and explored the potential intracellular signal transduction 
pathways involved in NED of NSCLC. We confirmed our findings 
using activators versus inhibitors to these signal transduction path-
ways in vitro. We also performed immunohistochemical stains of 
phospho-Erk1/2 of lung cancer specimens known to have NED and 
explored its clinical relevance.
Results: We discovered that NED of NSCLC was associated with 
the activation of Erk1/2-mitogen-activated protein kinases (MAPK) 
signal transduction pathway, and the inhibition of the Akt signal 
transduction pathway. Using specific activator (Pb2+) and inhibitors 
(siRNA-Erk1/2 and U0126) to the Erk1/2-MAP-kinase pathway, as 
well as the inhibitor (LY294002) to the Akt pathway, we found that 
Erk1/2-MAP-kinase activation was essential for NED of NCI-H157 
cells. Staining of Erk1/2-MAP-kinase pathway revealed a high rate 
of positivity in NSCLC tumors with NED when compared with other 
neuroendocrine lung tumors.
Conclusions: To our knowledge, our findings are the first to describe 
the potential involvement of Erk/MAPK signal transduction pathway 
of NSCLC in the association with NED. Further investigation of the 
Erk/MAPK signal transduction pathway of NSCLC may yield dis-
coveries in identifying specific molecular targets for the treatment of 
NSCLC with NED.
Key Words: Non–small-cell lung cancer, Neuroendocrine differen-
tiation, Cell signaling, Erk/mitogen-activated protein kinases.
(J Thorac Oncol. 2014;9: 50–58)
Lung cancer is the leading cause of cancer death among all cancer types. There are two general categories of lung 
cancer: small-cell lung cancer (SCLC) and non–small-cell 
lung cancer (NSCLC), which are differentiated by histologic 
appearance, clinical behavior, and cancer therapy responses. 
Although SCLC constitutes 15% to 20% of lung cancer diag-
noses, NSCLC is much more common and is composed of 
heterogenous histologic subtypes including adenocarcinoma, 
squamous cell carcinoma, and large-cell carcinoma.1
Neuroendocrine differentiation (NED) has been observed 
in approximately 25% to 33% of all lung tumors.2,3 Essentially, 
all SCLC and carcinoid tumors show distinct histological 
structure and stain positive to neuroendocrine markers such 
as neuroamines, neuropeptides, dense core secretory granules, 
chromogranin A, neuroendocrine-specific protein, and neuron-
specific enolase (NSE).3–9 It was later recognized that NED was 
not limited to SCLC and carcinoid, and it could involve NSCLC 
such as large-cell neuroendocrine carcinoma (LCNEC).10 
Subsequently, it was found that about 10% to 20% of NSCLC, 
including adenocarcinomas and squamous cell carcinomas, 
also exhibit some neuroendocrine properties despite being con-
sidered nonneuroendocrine types.2,11 It has been postulated that 
NED of NSCLC represents an intermediary transition between 
SCLC and NSCLC,12 or that NED may be a predictor of the 
response to chemotherapy or radiotherapy,13,14 as well as a 
predictor of shorter survival in patients with stage I adenocar-
cinoma of the lung.3,15 Irrespective of these observations, the 
clinical significance of NED of NSCLC remains unclear.
For SCLC, the mitogen-activated protein kinases 
(MAPKs) pathway via Raf and activated protein kinase C has 
been implicated in the regulation of growth and differentia-
tion through neuropeptides.16–18 Although much is known of 
the NED of SCLC, the molecular basis of NED in NSCLC is 
not well understood. Erk/MAPKs are widely expressed ser-
ine-threonine kinases comprising the three major subfamilies: 
extracellular-signal regulated kinases Erk 1 and 2 (Erk1/2), 
c-Jun N-terminal kinases (JNKs), and p38 kinase. The 
Erk1/2-MAPK (p44/42) signaling pathway can be activated 
in response to many factors like mitogens, growth factors, 
and cytokines.19 These are involved in many cellular events, 
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although their functions in regulating specific responses are 
quite different depending on the cell types.20,21 In vitro inves-
tigation of prostate cancer has shown that the activation of the 
Erk/MAP kinase pathway stimulates NED of LNCaP cells.22 
Constitutive activation of the MAPK pathway has been shown 
to contribute to malignant transformation of mammalian cells, 
and has been associated with aggressive neoplastic phenotype 
and cancer resistance to chemotherapy.23–25
We describe in this report, using an NSCLC cell line 
in vitro NED induction model, that the Erk/MAPK signal-
ing pathway may be involved in NED of NSCLC. We also 
explored whether another major intracellular signal pathway 
PI3-kinase/Akt pathway was involved, as both Erk1/2-MAPK 
pathway and PI3-kinases/Akt pathways were major intracellu-
lar signaling modules. To our knowledge, the investigation of 
molecular signaling pathways involving Erk/MAPK for NED 
of NSCLC has not been reported in the published literature. 
Because there has been interest in developing anticancer drugs 
that target the MAPK pathway in the past decade26–28 we think 
the investigation of the intracellular signal transduction path-
way involved with NED of NSCLC cells may reveal potential 
molecular targets for the treatment of NSCLC with NED.
MATERIALS AND METHODS
Materials
The human NSCLC squamous cell line NCI-H157 was 
obtained from Dr. Oh (Virginia Commonwealth University, 
Richmond, VA). RPMI1640, fetal bovine serum (FBS) were 
from Invitrogen (Carlsbad, CA); 8-bromoadenosine 3′,5′ 
cyclic monophosphate (cAMP), 3-isobutyl-1-methylxanthine 
(IBMX) and Bradford Reagent were from Sigma (St Louis, 
MO); monoclonal anti-NSE antibody was from DAKO 
(Carpinteria, CA); monoclonal glyceraldehyde-3-dehydroge-
nase, polyclonal Akt1,2,3 antibodies were from Santa Cruz 
Biotechnology (Santa Cruz, CA); siRNA-Erk1/2, monoclo-
nal antiphospho Akt (S473), anti-Erk 1/2, and antiphospho-
Erk 1/2(T202/Y204) were from Cell Signaling Technology 
(Danvers, MA); and radio-immunoprecipitation assay (RIPA) 
lysis buffer was from Upstate Cell Signaling Solution (Lake 
Placid, NY). U0126 (used at a final concentration of 10 µM) 
was from Calbiochem (San Diego, CA); LY294002 (used at 
final concentration of 20 µM) was from Cayman Chemical 
(Ann Arbor, MI); and Interfere-in Transfection Reagent was 
from Polyplus-Transfection (Illkirch, France).
Cell Culture and the Induction of NED
The NSCLC NCI-H157 cell line was cultured in RPMI 
1640 medium supplemented with 20 mM glutamine, 25mM 
HEPES, and 10 % FBS. Cells were first serum-starved by 
overnight incubation with serum-free medium (SFM) con-
taining 1 % bovine serum albumin. For the induction of NED, 
overnight serum-starved cells were treated with SFM contain-
ing 0.5 mM IBMX/0.5mM cAMP for 72 hours as described 
previously.29 For the cells without IBMX/cAMP treatment, the 
overnight serum-starved cells were treated with fresh SFM for 
the next 72 hours without the addition of IBMX/cAMP.
Western Blotting
Cells were washed twice with cold Dulbecco's phosphate 
buffered saline (DPBS) and lysed in RIPA buffer, scraped from the 
tissue culture plate, sheared through a 20-gauge needle, then cen-
trifuged at 14,000 rpm for 10 minutes. The cellular protein concen-
tration in the cell lysates was determined using the Bradford assay 
(Sigma, St. Louis, MO). Proteins were then separated on 10% 
sodium dodecyl sulfate (SDS) polyacrylamide gel and transferred 
to the nitrocellulose membrane using Semi-Dry Transfer Cell 
(Bio-Rad, Hercules, CA). Membranes were blocked with Tris-
Buffered Saline/0.5% Tween 20 containing 5% nonfat dry milk, 
incubated with the desired primary antibody diluted with Tris-
Buffered Saline/0.5% Tween 20 containing 3% nonfat dry milk. 
After incubation with the appropriate secondary antibody, proteins 
were detected with Immun-Star Western C kit (Bio-Rad, Hercules, 
CA). The ChemiDoc XRS Imaging System (Bio-Rad, Hercules, 
CA) was used to analyze the densitometry of Western blots.
siRNA Transfection
siRNA-Erk1/2 transfections were performed at 20 nM 
using the Interfere-in transfection reagent (Polyplus Transfections, 
Illkirch, France). The cells (1 × 106) were plated in 10-cm plates 
24 hours before experiment to reach density 30% to 50% at the 
day of the experiment and then transfected with siRNA-Erk1/2 
according to the manufacturer protocol. An Opti-MEM reduced 
serum medium (Invitrogen) was used during transfection.
Immunohistochemical Staining
Immunohistochemical (IHC) staining of lung cancer 
specimens was performed under the purview of a protocol 
approved by the Internal Review Board (PI: Haodong Xu). For 
IHC staining, sections (5 µm thick) were cut from formalin-
fixed and paraffin-embedded tissue specimens mounted on 
glass microscopic slides and air-dried overnight and then incu-
bated at 60°C for 1 hour. After conventional deparaffinization, 
the indirect IHC staining was performed. In brief, slides were 
subjected to an antigen retrieval procedure in 10 mM sodium 
citrate buffer, pH 6.0 at 99°C for 20 minutes, and then cooled 
to 60°C and then endogenous peroxidase was quenched in 3% 
hydrogen peroxide for 10 minutes. Next, the slides were incu-
bated with the rabbit monoclonal antibody phospho-Erk1/2 
(Thr202/Tyr204; Cell Signaling Technology, Danvers MA) 
diluted 1:400 for 30 minutes, followed by Flex-HRP Detection 
kit according to the manufacturer instructions (Dako, 
Carpinteria, CA) and then visualized with liquid 3,3′diami-
nobenzidine (DAKO), counterstained with hematoxylin and 
rinsed with PBS. The reading of the phospho-Erk1/2 stain was 
conducted by a pathologist on coded sample specimens.
Statistical Analysis
Statistical analysis was performed using the two-tail t test.
RESULTS
NED: Erk1/2 and Akt Phosphorylation
NED of NCI-H157 cells was induced in SFM contain-
ing NED induction compounds 0.5mM IBMX/0.5mM cAMP. 
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FIGURE 1.  NSE expression, phospho-Erk1/2 (T202/Y204) activation, and phospho-AKT inhibition of serum-starved cells 
(control), vs. cells in fresh SFM with IBMX/cAMP treatment (+IBMX/cAMP), vs. cell culture in fresh SFM without IBMX/cAMP 
(−IBMX/cAMP). Cells were harvested and equal amounts of cellular protein (60 µg per lane) were separated on 10% SDS poly-
acrylamide gel and immunoblotted with: (A) anti-NSE, (B) anti–phospho-Erk1/2 (T202/Y204), and (C) anti–phospho-Akt (S473) 
primary antibodies. Data showed that IBMX/cAMP treatment was associated with NSE induction, increased phospho-Erk1/2 
expression and the inhibition of phospho-Akt. Levels of GAPDH, total Erk1/2 protein, and total Akt protein were used as gel 
loading controls. Data represent the mean ± SD of three independent experiments. ***p<0.01; **p<0.05; *p=0.05. NSE, neuron-
specific enolase; NED, neuroendocrine differentiation; SFM, serum-free medium; IBMX, 3-isobutyl-1-methylxanthine; cAMP, 
cyclic monophosphate; GAPDH, glyceraldehyde-3-dehydrogenase. 
The results presented as part of Figures 1A–C were protein 
expression by Western blot analysis. Figure 1A shows a marked 
increase of NSE expression after 72 hours of incubation in 
SFM containing 0.5 mM IBMX/0.5mM cAMP. The incuba-
tion of cells in SFM without the differentiating agents IBMX/
cAMP seemed to also induce some NSE expression, but to a 
much lesser extent and did not reach a statistically significant 
level (p=0.24). Figure 1B shows that the NED of NCI-H157 
cells were accompanied by an increased phosphorylation of 
Erk1/2. In contrast, Akt was constitutively active in control cells 
(serum-starved overnight), and to a lesser extent in cells incu-
bated in SFM without the differentiating agents IBMX/cAMP 
(Fig. 1C). Cells with induced NED by IBMX/cAMP have much 
lower level of phosphorylated Akt, suggesting that Akt phos-
phorylation was inhibited in cells with NED (Fig. 1C).
Effect of U0126 on NSE Expression
U0126 is a highly selective inhibitor of MEK (MAP 
kinase) kinase (a kinase upstream of Erk1/2). On the basis of 
findings from Figure 1 that NED was associated with Erk1/2 
activation, we tested whether activation of Erk1/2 kinase was 
essential for NED of NCI-H157 cells. We induced NED of 
NCI-H157 cells with 0.5mM IBMX/0.5mM cAMP in the 
presence of 10 µM of U0126 to assess the effect of inhibition 
of Erk1/2 by U0126. Figure 2A demonstrates that U0126 did 
inhibit Erk1/2 phosphorylation, whereas Figure 2B shows 
that U0126 also inhibited NSE expression in NED cells. Our 
finding using U0126 further supported that Erk1/2 signaling 
pathway was essential in the in vitro induction of NED of 
NCI-H157 cells.
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Effect of Inhibition of Akt Phosphorylation  
on NSE Expression
In Figure 1C, we showed that NED of NCI-H157 cells 
was accompanied by the inhibition of Akt phosphorylation. 
It remained unclear whether the inhibition of Akt phos-
phorylation might lead to the NED of NCI-H157 cells. To 
test whether there was any causal relationship, we examined 
the effect of Akt phosphorylation inhibition by LY294002 
(20 µM) on NCI-H157 cells. Figure 3 shows that inhibition 
of Akt activation of NCI-H157 cells did not increase NSE 
expression in these cells. Such an observation demonstrates 
that Akt pathway was not essential for the NED of NCI-
H157 cells.
Effect of Silencing Erk1/2 Gene on NSE 
Expression in Neuroendocrine-Differentiated  
NSCLC Cells
To provide more direct evidence that the activation of the 
Erk1/2-MAPK pathway was essential for NED of NCI-H157 
cells, we applied the siRNA approach to silence the expression 
of the Erk1/2 protein. We sought to examine whether silencing 
Erk 1/2 gene expression might have any effect on NSE expres-
sion of these cells. Figure 4A shows that application of siRNA 
to silence the Erk1/2 gene significantly reduced the expression 
of Erk1/2 in NCI-H157 cells. Figure 4B shows that siRNA 
treatment to silence the Erk1/2 gene expression significantly 
decreased NSE expression in NCI-H157 cells.
Pb2+ Effect on Erk1/2 Activation 
and NSE Expression
It has previously been shown that Pb2+ ions can cause 
prolonged activation of Erk1/2 in lung cancer cell line 
CL3.30 To provide further evidence that Erk1/2-MAPK 
was involved in NED of NCI-H157 cells, we treated these 
cells with Pb2+ (30 µM) and assessed the effect on Erk1/2 
activation. We found that Pb2+ treatment led to a period 
of Erk1/2 activation, with maximum phosphorylation of 
Erk1/2 observed at 30 minutes after treatment. After the 
A
B
FIGURE 2. A, U0126 effect on Erk1/2 activation. B, U0126 effect on NSE expression of H157 cells. Serum-starved cells (con-
trol), vs. serum-starved cells in fresh serum-free culture medium with IBMX/cAMP (+IBMX/cAMP), vs. serum-starved cells 
without IBMX/cAMP (No IBMX/cAMP) were used in these experiments. Cells were either treated with 10µM U1026 (light gray) 
or not treated with U1026 (darker gray). Equal amounts of protein were separated by SDS polyacrylamide gel and immunob-
lotted with anti-NSE and antiphospho-Erk1/2(T202/Y204) antibodies. Data showed that U0126 inhibited the phosphorylation 
of Erk1/2 (A), and that U0126 treatment suppressed NSE expression in IBMX/cAMP-treated NCI-H157 cells (B). Together, data 
from (A) and (B) show that the inhibition of Erk1/2 activation by U0126 was associated with the suppression of NSE expression 
in IBMX/cAMP-treated cells. Levels of glyceraldehyde-3-dehydrogenase, total Erk1/2 and total Akt proteins were used as gel 
loading controls. Data represent the mean ± SD of three independent experiments. ***p<0.01; **p<0.05; *p=0.05. NSE, neuron-
specific enolase; NED, neuroendocrine differentiation; IBMX, 3-isobutyl-1-methylxanthine; cAMP, cyclic monophosphate.
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FIGURE 3.  Effect of LY 294002 (20µM) on (A) Akt activation, and (B) NSE expression of NCI-H157 cells. Serum-starved cells were 
treated with LY294002 in fresh serum-free culture medium. Equal amounts of cellular protein (60 µg per lane) were separated on 
10% SDS polyacrylamide gel and immunoblotted with (A) anti–phospho-Akt (S473) and (B) anti-NSE antibodies. Data showed 
that LY294002 inhibited the Akt activation while not affecting NSE expression. Data represent the mean ± SD of three independent 
experiments. ***p<0.01; **p<0.05; *p=0.05. NSE, neuron-specific enolase; GAPDH, glyceraldehyde-3-dehydrogenase. 
A B
FIGURE 4.  Effect of silencing Erk 1/2 gene by siRNA on Erk1/2 expression and NSE expression in NCI-H157 cells. Serum-starved 
cells were treated with 3-isobutyl-1-methylxanthine/cyclic monophosphate for 72 hours to induce NE differentiation in the pres-
ence or absence of siRNA-Erk1/2 as described in Materials and Methods. A, shows that silencing Erk1/2 gene expression by siRNA-
Erk1/2 in NE-differentiated NCI-H157 cells reduced the level of Erk1/2 expression. B, shows that silencing Erk1/2 gene expression 
was accompanied by the inhibition of NSE expression. Data represent the mean ± SD of three independent experiments. 
***p<0.01; **p<0.05; *p=0.05. NSE, neuron-specific enolase; NE, neuroendocrine; GAPDH, glyceraldehyde-3-dehydrogenase. 
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peak level of activation, the level of Erk1/2 phosphoryla-
tion declined over time and reached the baseline level by 
24 hours post Pb2+ treatment (Fig. 5A). Pb2+ treatment also 
led to an increased expression of NSE, with the maximum 
effect at 6 hours after Pb2+ treatment (Fig. 5B). Such data 
lent further support of the involvement of Erk1/2 activation 
in the NED of NCI-H157 NSCLC cells.
Phosphorylated Erk1/2 Expression in Lung  
Tumor Specimens
To determine whether the pathway of Erk1/2 pathway 
activation discovered in the lung cancer cell is relevant in 
NED of human NSCLC, we examined 39 lung tumor samples 
known to have NED, which included typical and atypical car-
cinoid, SCLC, and NSCLC. We conducted IHC staining for 
phosphorylated Erk1/2 expression of these tumors. Erk1/2 
positivity was defined by 95% or more tumor cells staining 
positive with phospho-Erk1/2 We found out that the positive 
rate of IHC was 0 of 10 (0%) for typical carcinoid; 2 of 10 
(20%) for atypical carcinoid; 4 of 9 (44.4%) for small-cell 
lung carcinoma; and was 7 of 10 (70%) for LCNEC. Examples 
of the hematoxylin and eosin stain and IHC stain for different 
histologies are shown in Figure 6. The Erk1/2 activation was 
statistically different (**p<0.01 by two-tailed Fisher’s exact 
test) comparing all carcinoid tumors (2 of 20, typical plus 
atypical) with high-grade neuroendocrine carcinoma (11 of 
19, SCLC plus NSCLC). The differences between individual 
histology types did not reach significance, likely because of 
small sample sizes.
DISCUSSION
NED is observed in essentially all SCLC of the lung, 
which exhibits distinct histopathologic appearances and 
clinical behavior. SCLC is very sensitive to both chemo-
therapy and radiation treatment whereas NSCLC is not. 
Among all NSCLC, NED of NSCLC has been observed in 
approximately 10 to 20% of conventional adenocarcinoma, 
squamous cell carcinoma, or large-cell carcinoma, but the 
clinical significance and optimal treatment of NSCLC with 
features of NED remain unclear. Further, the pathogenesis 
of NED in NSCLC is not clearly understood. Different stud-
ies have attempted to address the prognostic value of NED 
in NSCLC. Some reported that NED in NSCLC identified 
a subset of tumors with poorer prognosis and reduced life 
expectancy in patients with stage I pulmonary adenocarci-
nomas.3 Others reported that NED might be of prognostic 
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FIGURE 5.  Effect of Pb2+ treatment on Erk1/2 activation and NSE expression. Serum-starved NCI-H157 cells were treated 
with serum-free culture medium containing Pb2+ (30 µM) for up to 24 hours. Cells were harvested at 0.5-hour, 6-hour, and 
24-hour time points, and equal amounts of cellular protein were separated on 10% SDS polyacrylamide gel and immunoblot-
ted with: (A) anti-phospho Erk1/2(T202/Y204) and (B) anti-NSE antibodies. Data show that Pb2+ treatment transiently activated 
Erk1/2 phosphorylation (A), and increased the expression of NSE (B) with somewhat different time course. Data represent the 
mean ± SD of three independent experiments. ***p<0.01; **p<0.05; *p=0.05. NSE, NSE, neuron-specific enolase.
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significance in patients with advanced-stage NSCLC treated 
with chemotherapy.14 Yet other studies indicated that there 
was no correlation between NED of NSCLC and disease-
specific and overall survival.31–34
Erk/MAPK pathway through Raf-1 and protein kinase 
C activation has been implicated in the regulation of growth 
by neuropeptides regarding the neuroendocrine nature of 
SCLC,16,17 and may be responsible for the development of the 
great majority of neuroendocrine foci in lung cancer cells. In 
this report, we induced NED of the NSCLC cell line NCI-
H157 and investigated the intracellular signal transduction 
pathways associated with NED. We would like to point out 
that the NCI-H157 cell line served only as an investigational 
model for the in vitro induction of NED, which allowed us 
to investigate potential molecular pathways involved with 
NED. This cell line has previously been used by other inves-
tigators for NED induction in vitro as well.29 We found that 
NED of NCI-H157 was associated with the activation of 
Erk1/2-MAPK pathway and the inhibition of the Akt pathway. 
Our data showed that the activation of Erk/MAPK pathway 
was essential to NED of the cell line NCI-H157 (Fig.1) in 
that we consistently observed reduction of NSE expression 
(NED marker) after treatment of differentiating NCI-H157 
cells with MEK inhibitor U0126 (Fig. 2), and with specific 
siRNA approach where expression of Erk1/2 protein was sup-
pressed. The latter was correlated with the inhibition of NSE 
expression (Fig. 4). When cells were treated with LY294002, 
an inhibitor to Akt signal transduction pathway, we did not 
observe changes of the expression of NSE. Taken together, 
our data support that in this culture model, the activation of 
Erk1/2-MAPK signal transduction pathway was essential for 
NED of NCI-H157 cells, whereas the inhibition of the Akt 
pathway was not.
The ErK1/2-MAPK pathway can be activated in many 
cell types by a broad spectrum of extracellular stimuli 
causing different physiological responses, most often cell 
division proliferation, and differentiation.35,36 It has been 
shown that aberrant expression and/or mutations of the 
Erk/MAPK signal transduction pathway were associated 
with human cancer.19,21,37 Sustained activation of Erk1/2-
MAPK via Ras-Raf-MEK1/2 has been reported in several 
types of cancer including kidney, colon, lung, prostate,37 
FIGURE 6.  Histologic types by hematoxylin and 
eosin (A–D) and Erk1/2 expression (E–H) of human 
neuroendocrine lung tumors. Neuroendocrine 
tumors of the lung are classified into typical carci-
noid (A, E), atypical carcinoid (B, F) and SCLC (C, G), 
and LCNEC (D, H). Among these tumors, LCNEC (H) 
is strongly positive, followed by SCLC (G), whereas 
typical carcinoid (E) and atypical carcinoid (F) are 
mostly negative. SCLC, small-cell lung carcinoma; 
LCNEC, large-cell neuroendocrine carcinoma.
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and esophagogastric malignancies.38 Other studies20,38 have 
provided evidence that Erk/MAPK activation in cancer 
could be MEK independent, or that at least PI3K or conven-
tional protein C kinase isoforms could contribute to MEK-
independent Erk activation.
In our observation, the Erk1/2 activation was corre-
lated well with human lung cancers that undergo NED. The 
choice of LCNEC was to take a clearly defined histologic type 
of NSCLC with NED to compare with lung cancer of other 
distinct histology with NED as well, that is, small cell and 
carcinoid. Findings from this article serve as the basis for us 
to extend the investigation to include specimens of NSCLC 
with unexpected NED irrespective of histologic subtype (such 
as adenocarcinoma and squamous cell carcinoma) for the 
ERk1/2 activation. The high rate (70%) of positivity of phos-
phorylated Erk1/2 stain seen in LCNEC, a type of NSCLC, 
and the much lower rates of positivity in other lung tumors 
known for NED (0% for typical carcinoid, 20% for atypical 
carcinoid and 40% for SCLC) is interesting. It proves that 
the Erk/MAPK signal transduction pathway is likely one of 
the mechanisms for the NED of NSCLC. SCLC positivity is 
noted at 44.4%, suggesting that the NED of some SCLC may 
share similar pathway of NED with NSCLC. We acknowledge 
that the sample size of 39 was small; additional investigations 
using a larger sample size will be more informative.
To our knowledge, our finding is the first to describe the 
potential involvement of Erk/MAPK signal transduction path-
way of NSCLC in association with NED. Among the MAP 
kinase pathways, the inhibition of Erk/MAPK pathway has 
made some progress in drug development.39,40 For example, 
sorafenib was shown to block the Raf/MEK/ERK pathway, 
inhibits tumor angiogenesis, and induces tumor cell apopto-
sis in hepatocellular carcinoma model PLC/PRF/5.41 Future 
research in this direction may help to discover molecular tar-
geted therapy for NSCLC with NED.
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